3Barnes PJ, Celli BR. Systemic manifestations and co- morbidities of COPD[J]. European Respiratory Jour- nal,2009,33(5) :1165-1185.
4Graat-Verboom L,Wouters EFW, Smeenk FW, et al. Cur- rent status of research on osteoporosis in COPD: a system- atic review[J]. Eur Respir J ,2009,34(1) :209-218.
5Pobeha P, Ukropec J, Skyba P, Ukropcova B, et al. Re- lationship between osteoporosis and adipose tissue lep- tin and osteoprotegerin in patients with chronic ob- structive pulmonary disease [J]. Bone, 2011, 48 ( 5 ): 1008-1014.
6Pobeha P, Petrasova D, Tkacova R, et al. Circulatory osteo- protegerin is related to osteoporosis of the hip in patients with COPD[J]. Respir Med, 2014,108(4) : 621-627.
7Vega D,Maalouf NM,Sakhaee K. The role of receptor activator of Nuclear factor-kB(RANK)/RANK ligand/ osteoprotegerin: clinical implications[J]. Clinical Endo- crinology Metabolism,2007,92(12) :4514-4521.
8Bai P, Sun Y, Jin J, et al. Disturbance of the OPG/ RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis[J]. Respir Res,2011,12:157.
9Duckers JM, Evans BA, Fraser WD, et al. Low bone mineral density in men with chronic obstructive pul- monary disease[J]. Respir Res, 2011,12 ( 1 ) : 101.
10Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis[J]. Chest, 2011,139 (3) :648-657.
